Table 5. Estimated prevalence and diagnostic tests' sensitivity and specificity by survey.
| Country | Estimated true prevalence | Estimated sensitivity and specificity | |||||
| Microscopy | ELISA | PCR | |||||
| se | sp | se | sp | se | sp | ||
| Vietnam | 0.12 | 0.53 | 0.95 | 0.55 | 0.80 | 0.95 | 0.97 |
| CI lower 95% limit | 0.01 | 0.42 | 0.94 | 0.42 | 0.78 | 0.89 | 0.95 |
| CI upper 95% limit | 0.15 | 0.70 | 0.96 | 0.70 | 0.82 | 1.00 | 1.00 |
| Peru Iquitos | 0.03 | 0.90 | 0.98 | 0.79 | 0.88 | 0.98 | 0.99 |
| CI lower 95% limit | 0.01 | 0.72 | 0.96 | 0.62 | 0.84 | 0.95 | 0.98 |
| CI upper 95% limit | 0.05 | 1.00 | 0.99 | 0.95 | 0.91 | 1.00 | 1.00 |
| Peru Jaen | 0.00 | 0.89 | 1.00 | 0.85 | 0.88 | 0.98 | 1.00 |
| CI lower 95% limit | 0.00 | 0.71 | 1.00 | 0.64 | 0.85 | 0.95 | 0.99 |
| CI upper 95% limit | 0.01 | 1.00 | 1.00 | 1.00 | 0.91 | 1.00 | 1.00 |
| Cambodia S1 | 0.01 | 0.89 | 0.96 | 0.85 | 0.90 | ||
| CI lower 95% limit | 0.00 | 0.71 | 0.95 | 0.63 | 0.88 | ||
| CI upper 95% limit | 0.02 | 1.00 | 0.98 | 1.00 | 0.91 | ||
| Cambodia S2 | 0.01 | 0.89 | 0.98 | 0.84 | 0.79 | ||
| CI lower 95% limit | 0.00 | 0.71 | 0.96 | 0.62 | 0.77 | ||
| CI upper 95% limit | 0.03 | 1.00 | 0.99 | 1.00 | 0.82 | ||
CI = credibility interval; Se = sensitivity; Sp = specificity; ELISA = Enzyme-Linked Immunosorbent Assay; PCR = Polymerase Chain Reaction; S1 = survey 1; S2 = survey 2.